Home › Trials › NCT06658899

Phase 2 test of CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

Phase 2 Interventional Cardurion Pharmaceuticals, Inc. · NCT06658899

This trial will test whether two doses of the experimental drug CRD-4730 are safe and affect exercise-induced dangerous heart rhythms in adults with CPVT.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment12 (estimated)
Ages18 Years to 99 Years
SexAll
SponsorCardurion Pharmaceuticals, Inc. Industry-sponsored
Drugs / interventionsradiation
Locations9 sites (San Francisco, California and 8 other locations)
Trial IDNCT06658899 on ClinicalTrials.gov

What this trial studies

This is a Phase 2, multicenter, double-blind, sponsor-blinded, placebo-controlled, repeat-dose crossover trial of CRD-4730 in adults with genetically confirmed CPVT. Each participant is randomized to a 3-period, 3-sequence schedule in which they receive two different active doses and one matching placebo, with safety, tolerability, pharmacokinetics, and pharmacodynamics measured across periods. Participants must be able to perform an exercise stress test that provokes frequent PVCs or higher-grade ventricular arrhythmia and generally remain on a stable antiarrhythmic regimen prior to enrollment. The study is conducted at Cardurion investigational sites in San Francisco, Morrisville, and Houston.

Who should consider this trial

Good fit: Adults (≥18) with a confirmed pathogenic RYR2 mutation, a CPVT clinical phenotype, the ability to perform an exercise stress test showing frequent PVCs or higher-grade arrhythmia, and on a stable antiarrhythmic regimen (not including amiodarone) are ideal candidates.

Not a fit: Patients without a confirmed RYR2-related CPVT diagnosis, those unable to perform an exercise stress test, pediatric patients under 18, or those on amiodarone are unlikely to be eligible or benefit from this protocol.

Why it matters

Potential benefit: If successful, CRD-4730 could reduce exercise-triggered ventricular arrhythmias and lower the risk of life-threatening heart rhythm events in people with CPVT.

How similar studies have performed: Targeting CaMKII-related pathways in CPVT is a relatively novel approach with limited prior clinical data, so effectiveness in humans remains unproven to date.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Each participant must meet all the following criteria to be enrolled in this study:

1. The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements.
2. The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.
3. The participant can perform an EST during which frequent premature ventricular contractions (PVCs; ≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the Investigator.
4. The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.
5. Adheres to all contraceptive criteria.

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study:

1. The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
2. The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT.
3. The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.
4. The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening.
5. The participant has an anticipated change in exercise regimen or new exercise program during the course of the study.
6. The participant has a history of malignancy within the past 5 years at Screening, with the exception of successfully treated basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin or cervical carcinoma in situ. Prior exposure to chest radiation for any malignancy is exclusionary.
7. The participant has abnormal blood pressure, defined as supine symptomatic hypotension, systolic blood pressure \>150 mm Hg or diastolic blood pressure \>90 mm Hg, or symptomatic bradycardia or a heart rate \>100 bpm at Screening and/or on Day 1. Blood pressure and pulse should be measured after the participant has been in the seated position after 5 minutes of rest.
8. The participant has hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × (upper limit of normal \[ULN\]) and/or total bilirubin \>1.5 × ULN at Screening (unless secondary to confirmed Gilbert syndrome).
9. The participant has acute or chronic hepatitis B (HBV; defined as hepatitis B surface antigen \[HBsAg\] reactive), acute or chronic hepatitis C virus (HCV; defined as detection of HCV antibody and RNA \[qualitative\]), or human immunodeficiency virus (HIV) infection.
10. The female participant is pregnant, lactating/breastfeeding, or has plans to become pregnant during the study or within 3 months following the last study drug administration.
11. The participant has taken any antiarrhythmic drug in addition to their stable, chronic regimen unless it has been at least 5 half-lives since administration at the time of Screening.

Where this trial is running

San Francisco, California and 8 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Catecholaminergic Polymorphic Ventricular TachycardiaCaMKIICPVTVentricular TachycardiaCRD-4730CardiovascularArrhythmiaCaM kinase II
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.